Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation

Ilona Hartmane; Iveta Ivdra; Ingmārs Mikažāns; Vanda Bondare-Ansberga

doi:10.2478/prolas-2021-0052

Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation

Ilona Hartmane (Corresponding Author), Iveta Ivdra, Ingmārs Mikažāns, Vanda Bondare-Ansberga

Department of Dermatology and Venereology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

20 Downloads (Pure)

Abstract

Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.

Original language	English
Pages (from-to)	357-363
Number of pages	7
Journal	Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
Volume	75
Issue number	5
DOIs	https://doi.org/10.2478/prolas-2021-0052
Publication status	Published - 1 Oct 2021

Keywords*

TNF-a inhibitors
adalimumab
parameters of cellular and humoral immunity
T cells

Field of Science*

3.2 Clinical medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.2478/prolas-2021-0052Licence: CC BY-NC-ND

Correlation of immunological and clinical changesFinal published version, 1.06 MBLicence: CC BY-NC-ND

Cite this

Hartmane, I., Ivdra, I., Mikažāns, I., & Bondare-Ansberga, V. (2021). Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences., 75(5 ), 357-363. https://doi.org/10.2478/prolas-2021-0052

Hartmane, Ilona ; Ivdra, Iveta ; Mikažāns, Ingmārs et al. / Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs : one-year dynamic observation. In: Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2021 ; Vol. 75, No. 5 . pp. 357-363.

@article{44366d01dfa34d26aed323ee005baa0d,

title = "Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation",

abstract = "Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.",

keywords = "TNF-a inhibitors, adalimumab, parameters of cellular and humoral immunity, T cells",

author = "Ilona Hartmane and Iveta Ivdra and Ingmārs Mika{\v z}āns and Vanda Bondare-Ansberga",

year = "2021",

month = oct,

day = "1",

doi = "10.2478/prolas-2021-0052",

language = "English",

volume = "75",

pages = "357--363",

journal = "Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.",

issn = "2255-890X",

publisher = "de Gruyter",

number = "5 ",

}

Hartmane, I , Ivdra, I , Mikažāns, I & Bondare-Ansberga, V 2021, 'Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation', Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences., vol. 75, no. 5 , pp. 357-363. https://doi.org/10.2478/prolas-2021-0052

Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation. / Hartmane, Ilona (Corresponding Author); Ivdra, Iveta ; Mikažāns, Ingmārs et al.
In: Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences., Vol. 75, No. 5 , 01.10.2021, p. 357-363.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs

T2 - one-year dynamic observation

AU - Hartmane, Ilona

AU - Ivdra, Iveta

AU - Mikažāns, Ingmārs

AU - Bondare-Ansberga, Vanda

PY - 2021/10/1

Y1 - 2021/10/1

N2 - Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.

AB - Psoriasis is one of the most common autoimmune dermatoses with a chronic relapsing course. Biologic therapy should be initiated for patients with moderate to severe psoriasis when conventional systemic therapy and phototherapy are ineffective, or their use is limited due to comorbidities. In Latvia, adalimumab is the first choice of biologic drugs for treatment of psoriasis. The correlation between changes in cellular and humoral immunological parameters and clinical signs based on immunological data from psoriasis patients are evaluated in the publication.

KW - TNF-a inhibitors

KW - adalimumab

KW - parameters of cellular and humoral immunity

KW - T cells

UR - https://www.mendeley.com/catalogue/0af89e08-3ce3-352f-9c0e-c3a0732bcc51/

U2 - 10.2478/prolas-2021-0052

DO - 10.2478/prolas-2021-0052

M3 - Article

SN - 2255-890X

VL - 75

SP - 357

EP - 363

JO - Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

JF - Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

IS - 5

ER -

Hartmane I , Ivdra I , Mikažāns I , Bondare-Ansberga V. Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 2021 Oct 1;75(5 ):357-363. doi: 10.2478/prolas-2021-0052

Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated with Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: one-year dynamic observation

Abstract

Keywords*

Field of Science*

Publication Type*

Access to Document

Other files and links

Fingerprint

Cite this